Clinical Trial of Several Contact Lenses in Extended Wear

NCT ID: NCT00762788

Last Updated: 2015-06-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

350 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-02-28

Study Completion Date

2009-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is to clinically evaluate currently marketed contact lenses when used in an extended wear modality of up to seven days/six nights.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

senofilcon A contact lens

ACUVUE OASYS

Group Type ACTIVE_COMPARATOR

senofilcon A

Intervention Type DEVICE

1 week extended wear contact lens

lotrafilcon A contact lens

NIGHT\&DAY

Group Type ACTIVE_COMPARATOR

lotrafilcon A

Intervention Type DEVICE

1 week extended wear contact lens

lotrafilcon B contact lens

O2Optix

Group Type ACTIVE_COMPARATOR

lotrafilcon B

Intervention Type DEVICE

1 week extended wear contact lens

balafilcon A contact lens

PureVision

Group Type ACTIVE_COMPARATOR

balafilcon A

Intervention Type DEVICE

1 week extended wear contact lens

comfilcon A contact lens

Biofinity

Group Type ACTIVE_COMPARATOR

comfilcon A

Intervention Type DEVICE

1 week extended wear contact lens

etafilcon A contact lens

ACUVUE 2

Group Type ACTIVE_COMPARATOR

etafilcon A

Intervention Type DEVICE

1 week extended wear contact lens

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

senofilcon A

1 week extended wear contact lens

Intervention Type DEVICE

lotrafilcon A

1 week extended wear contact lens

Intervention Type DEVICE

lotrafilcon B

1 week extended wear contact lens

Intervention Type DEVICE

balafilcon A

1 week extended wear contact lens

Intervention Type DEVICE

comfilcon A

1 week extended wear contact lens

Intervention Type DEVICE

etafilcon A

1 week extended wear contact lens

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be of legal age, and be between 18 and 39 years of age.
* Signed Written Informed Consent and Investigator to record this on Case Report Form (CRF) in appropriate space.
* Require a visual correction in both eyes (Monovision not allowed)
* Require a soft contact lens spherical correction between -0.50 and -9.00D.
* Have an astigmatic correction less than 1.50D in both eyes.
* Be able to wear the lens powers available for this study.
* Be able to regularly wear the lenses on a 7 day/6 night extended wear basis (e.g. does not regularly swim more than once a week)
* Be correctable to a visual acuity of 20/30 or better in each eye.
* Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having:
* No amblyopia.
* No evidence of lid abnormality or infection.
* No clinically significant slit lamp findings
* No other active ocular disease.
* No previous ocular surgery.

Exclusion Criteria

* Requires concurrent ocular medication.
* Any systemic illness which would contraindicate lens wear or the medical treatment of which would affect vision or successful lens wear.
* No Clinically significant (Grade 3 or 4) slit lamp findings including corneal edema, corneal vascularization, corneal staining, tarsal abnormalities, bulbar injection, or any other abnormality of the cornea that would contraindicate contact lens wear.
* Diabetic.
* Infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g., HIV).
* PMMA or RGP lens wear in the previous 8 weeks.
* Has had refractive surgery. Has had eye injury/surgery within 8 weeks immediately prior to enrolment for this study.
* Abnormal lacrimal secretions.
* Pre-existing ocular irritation that would preclude contact lens fitting.
* Keratoconus or other corneal irregularity.
* Pregnancy, lactating or planning a pregnancy at the time of enrollment only.
* Participation in any concurrent clinical trial.
* Currently wearing B\&L PureVision, Ciba O2 Optix, Ciba Night \& Day, CooperVision Biofinity, Vistakon ACUVUE® OASYS, or Vistakon ACUVUE®2 on an EW basis
* Has had previous adverse event(s) contraindicating EW e.g. MK or greater than 2 corneal scars which appear to be contact lens related (e.g. not trauma related).
* Has had an eye injury or surgery within the last eight weeks.
Minimum Eligible Age

18 Years

Maximum Eligible Age

39 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Johnson & Johnson Vision Care, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Vision Research Foundation

Chennai, Tamil Nadu, India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CR-4472

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.